Recurrence of esthesioneuroblastoma with non-contiguous intracranial metastasis is possible 19 years after remission, a review suggests.
In a first-in-human trial of patients with solid tumors, a MYC inhibitor appeared tolerable and enabled nearly half of evaluable patients to maintain stable disease.
Durvalumab plus IMRT proved no more effective than cetuximab plus IMRT in patients with treatment-naïve, locoregionally advanced head and neck squamous cell carcinoma.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
The incidence of cutaneous adverse events in cancer patients receiving PI3K inhibitors may be as high as 29%, a meta-analysis suggests.
Inpatient treatment with immune checkpoint inhibitors is associated with poor survival outcomes in patients with advanced cancer.
Researchers sought to increase the rate of serious illness conversations between clinicians and patients with cancer.
Active surveillance may be a viable management strategy for most diagnosed thyroid cancers, according to researchers.
The approvals were based on data from the LIBRETTO-001 trial.
Donafenib demonstrated efficacy in patients with progressive, locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.
Neoadjuvant pembrolizumab does not appear to increase rates of postoperative adverse events in patients with advanced head and neck cancer.
Adding pembrolizumab to chemoradiotherapy did not improve event-free survival or overall survival.
Cancer developed in 22% of patients diagnosed with chronic kidney disease at ages 50 to 80 years, which is higher than the lifetime risk of cancer in the general population, according to investigators.
At 5 years, the rate of local control was 62.2%, and the overall survival rate was 49.8%.
Immune checkpoint inhibitor therapy appears to maintain or improve quality of life in patients with solid tumor malignancies.
Grouping Asian and Pacific Islander patients together may hide disparities in cancer outcomes between these groups, according to researchers.
Men tend to have a higher risk of cancer than women, and factors such as smoking, alcohol use, and diet do not appear to explain this disparity.
Cancer patients with HIV do not receive curative or palliative care in the same way as their HIV-negative peers.
Detection of ctDNA and early changes in ctDNA levels may predict treatment outcomes in patients with advanced solid tumors.
Many thyroid cancers are discovered in patients who undergo surgery without thyroid-referable symptoms, an international study suggests.